Improved cyclodextrin based erythropoietin formulation

Details Improved cyclodextrin based erythropoietin formulation Improved cyclodextrin based erythropoietin formulation

A - Human Necessities

61

K

A61K 47/40 (2006.01) A61K 38/18 (2006.01) A61K 47/48 (2006.01)

Patent

CA 2074820

The present invention relates to a new pharmaceutical composition for parenteral and local administration comprising an aqueous solution of erythropoietin and a .beta.-/ or .gamma.-cyclodextrin hydroxyalkyl derivative. The invention also relates to novel lyophi- lized or spray-dried erythropoietin compositions comprising a .beta.- or .gamma.-cyclodextrin hydroxyalkyl derivative, to processes for pre- paring such aqueous, lyophilized or spray-dried compositions and to a method for simultaneously stabilizing erythropoietin in an aqueous solution and preventing it from being adsorbed to surfaces.

Affiliated with

Also associated with

Rating

Improved cyclodextrin based erythropoietin formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Improved cyclodextrin based erythropoietin formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Improved cyclodextrin based erythropoietin formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1886568